Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $20.95 USD
Change Today -0.18 / -0.85%
Volume 531.2K
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

biomed realty trust inc (BMR) Key Developments

BioMed Realty Trust Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for Second, Third, Fourth Quarter and the Full Year 2015

BioMed Realty Trust Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's total revenues were $178.0 million compared with $168.9 million a year ago. Net income was $20.8 million compared with $20.8 million a year ago. Net income attributable to the company was $17.3 million or $0.08 per basic and diluted share compared with $18.8 million or $0.10 per basic and diluted share a year ago. FFO attributable to common shares and units was $85.3 million or $0.41 per diluted share compared with $83.4 million or $0.40 per diluted share a year ago. CFFO was $85.7 million or $0.41 per diluted share compared with $84.6 million or $0.41 per diluted share a year ago. AFFO attributable to common shares and units was $75.4 million or $0.36 per diluted share compared with $79.5 million or $0.38 per diluted share a year ago. Rental revenue was $118 million for the quarter, down slightly as a result of the cessation of rents from recent opportunistic lease terminations and the sale of 9911 Belward Campus Drive asset in the fourth quarter of 2014. Significant items impacting CFFO and FFO included an approximate $0.08 benefit from lease termination revenue recognized in the quarter, including fees received from Vertex. For the second and third quarters, the company expects cash, same property NOI to decline between 4% and 6% in each quarter. Fourth quarter results will improve, but will still be down year-over-year approximately 1%. For 2015, the company projected net income per diluted share attributable to common stockholders in the range of $0.32 to $0.40. The company projected FFO and CFFO per diluted share in the range of $1.61 to $1.69.

BioMed Realty Trust Inc. to Report Q1, 2015 Results on Apr 28, 2015

BioMed Realty Trust Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on Apr 28, 2015

BioMed Realty Trust Inc., Q1 2015 Earnings Call, Apr 29, 2015

BioMed Realty Trust Inc., Q1 2015 Earnings Call, Apr 29, 2015

BioMed Realty Trust Inc. Signs 10-Year Lease Agreement with Biogen in Cambridge

BioMed Realty Trust Inc. announced that it has signed a new 10-year lease agreement with Biogen for around 80,000 sqft of class A laboratory and office space at 301 Binney Street property in Cambridge, Massachusetts. Biogen will use this new space to expand its drug discovery efforts in this core life science district. With the lease of the fifth floor to Biogen, BioMed Realty has fully leased the 417,000 square foot 301 Binney Street property. Biogen joins Ironwood Pharmaceuticals and Living Proof located at this prime laboratory and office building.

BioMed Realty Trust Inc. Signs Alnylam Pharmaceuticals to 295,000 Square Foot Lease for Class A Laboratory and Office Space in Cambridge

BioMed Realty Trust Inc. announced the signing of a 295,000 square foot lease at 675 West Kendall by Alnylam Pharmaceuticals in Cambridge, Massachusetts providing Alnylam with Class A laboratory and office space in the heart of Kendall Square. Alnylam Pharmaceuticals is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. This growing life science company will occupy all the rentable space available on the six floors of 675 West Kendall when the lease with the current tenant, Vertex Pharmaceuticals, ends in May 2018.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMR:US $20.95 USD -0.18

BMR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
American Campus Communities Inc $39.17 USD +0.05
Douglas Emmett Inc $29.49 USD +0.02
Equity LifeStyle Properties Inc $54.05 USD +0.30
Home Properties Inc $74.96 USD +0.06
Post Properties Inc $57.22 USD +0.08
View Industry Companies
 

Industry Analysis

BMR

Industry Average

Valuation BMR Industry Range
Price/Earnings 23.1x
Price/Sales 6.4x
Price/Book 1.4x
Price/Cash Flow 9.4x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMED REALTY TRUST INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.